JKJerome O. Klein

Jerome O. Klein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jerome O. Klein has a total of 451 co-authors. Here are the top co-authors by number of shared publications:

  • David W Teele

    The Greater Boston Collaborative Otitis Media Study Group, Boston University School of Medicine Harvard Medical School, Boston City Hospital, Dept. of Pediatrics, Boston

    3 shared publications
  • Bernard Rosner

    The Greater Boston Collaborative Otitis Media Study Group, Boston University School of Medicine Harvard Medical School, Boston City Hospital, Dept. of Pediatrics, Boston

    2 shared publications
  • Martin G. Myers

    Department of Pediatrics and Preventive Medicine, University of Texas, Medical Branch, Galveston, Texas

    2 shared publications
  • A. Clinton White

    1 shared publication
  • A. George Smulian

    1 shared publication
  • Adrian V.S. Hill

    1 shared publication

Latest Publications

    • 1 September 2010
      • Vol. 16  (9) , e235-44

    Benefits and risks of live attenuated influenza vaccine in young children.

    by Gerry Oster, Derek Weycker, John Edelsberg, Kristin L Nichol, Jerome O Klein, Robert B Belshe

    To examine the benefit-risk profile of live attenuated influenza vaccine (LAIV) across a range of clinical scenarios in which we varied assumptions regarding both the percentage of children who would receive LAIV in lieu of trivalent inactivated influenza virus (TIV) and the extent of off-label use. Model of expected benefits and risks of immunization of young children against influenza. We estimated expected numbers of cases of influenza illness (FLU), medically significant wheezing (MSW), and hospitalization in a single influenza season under alternative assumptions regarding use of LAIV in lieu of TIV, based on projections from a large phase III trial. Assuming no use of LAIV in nonindicated children (aged <24 months and those with history of recurrent wheezing or asthma), and 50% use in lieu of TIV among children in the indicated population, there would be 2099 fewer FLU cases per 100,000 children aged 12 to 59 months, and no change in MSW or hospitalization. If LAIV also were used in lieu of TIV among 20% of children aged 12 to 23 months and 20% of children aged 24 to 59 months with a history of recurrent wheezing or asthma, there would be a further reduction of 397 FLU cases and 12 hospitalizations per 100,000 children aged 12 to 59 months, but 51 additional MSW cases. Our study suggests that even if LAIV were sometimes used inadvertently in clinical practice in young children for whom it is not indicated, the overall balance of expected benefits and risks would remain favorable.


  • CONTRIBUTORS

    by N. Franklin Adkinson, David M. Allen, Ban Mishu Allos, Guy W. Amsden, David A. Anderson, David R. Andes, Fred Y. Aoki, Petra M. Apfalter, Michael A. Apicella, Cesar A. Arias, et al.

  • Open Access

    Danger Ahead: Politics Intrude in Infectious Diseases Society of America Guideline for Lyme Disease

    by Jerome O. Klein

    In the fall of 2006, the Infectious Diseases Society of America (IDSA) received a subpoena from the Attorney General (AG) of Connecticut, Richard Blumenthal. Th


  • Streptococcus pneumoniae

    by Georges Peter, Jerome O. Klein


  • Open Access

    Robert Austrian: 1917-2007

    by Jerome O. Klein, Stanley A. Plotkin

    Robert Austrian, pioneer in the development of pneumococcal vaccines and past president of the Infectious Diseases Society of America, died on 25 March 2007 after experiencing a stroke. He was 90 years old. He had been in good health and maintained a 6-day-a-week work schedule as a hands-on Director of the World Health Organization Collaborating Center for Reference and Research on Pneumococci until a few days before his death.


  • Vaccine Shortages: Why They Occur and What Needs to Be Done to Strengthen Vaccine Supply

    by Jerome O. Klein, Martin G. Myers

    Vaccine shortages have been a frequent problem during the past 50 years, but most shortages have been associated with a single product and were of short duration with minimal disruption to national immunization programs. In 2001 attention was directed to the vulnerability of the vaccine supply when, for various reasons, 8 of the 11 vaccines recommended for universal immunization of infants and children were unavailable or in short supply. In addition, tetanus toxoid was in short supply and needed to be prioritized for emergency use only. Although most of these shortages resolved in the following year, periodic shortages of pneumococcal conjugate vaccine (Prevnar; Wyeth Vaccines, Collegeville, PA) continued into 2004. The shortage of trivalent inactivated influenza virus vaccine (TIV) in the fall of 2004 was reported each night on national and local news and was the subject of Congressional inquiries. The legislators wanted to know why this country with vast resources and huge manufacturing capability was unable to provide a reliable supply of routinely recommended vaccines. The immediate answer to the Congressional inquiry about influenza vaccine shortage was the contamination problem at the Chiron plant in Liverpool, England. However, there are substantive problems with domestic vaccine-manufacturing capacity; shortages will likely continue to occur until core problems are addressed. Since 2002, concern about the vulnerability of vaccine production and supply has been the subject of workshops convened by the National Vaccine Advisory Committee (NVAC) of the Department of Health and Human Services,1,2 the focus of a Congressional accounting office report,3 was discussed at a colloquium of the Sabin Institute,4 has been considered by the Institute of Medicine (IOM),5 and is extensively reviewed in a series of articles about development, financing, and implementation of vaccine programs.6 Pediatricians are called on to modify vaccine schedules when … Address correspondence to Jerome O. Klein, MD, Pediatric Infectious Diseases, Finland 5, Boston Medical Center, 774 Albany St, Boston, MA 02118. E-mail: jerome.klein{at}bmc.org


  • Open Access

    Strengthening the Supply of Routinely Administered Vaccines in the United States: Problems and Proposed Solutions

    by Jerome O. Klein, Martin G. Myers

    At the request of the Assistant Secretary for Health of the United States Department of Health and Human Services, the National Vaccine Advisory Comm


  • Open Access

    Strengthening the Supply of Routinely Administered Vaccines in the United States: Progress and Problems—2005

    by Jerome O. Klein, Charles M. Helms

    In February 2002, the National Vaccine Advisory Committee (NVAC), acting on a request from the Assistant Secretary for Health of the US Department of Health and Human Services, organized a workshop to identify reasons for vaccine shortages and to develop strategies and solutions to prevent future shortages. A report was prepared for the Assistant Secretary and was summarized in an article published in the Journal of the American Medical Association in 2003 [1]. The report concluded that the disruptions in the vaccine supply were likely to continue, and the following strategies were recommended: evaluating appropriate financial incentives for manufacturers, streamlining the regulatory process without compromising safety or efficacy, increasing support for regulatory agencies, expanding vaccine stockpiles, maintaining and strengthening liability protections, improving communication among stakeholders, increasing the availability of public information, and developing a campaign emphasizing the benefits of vaccination.


  • Management of the febrile child without a focus of infection in the era of universal pneumococcal immunization

    by Jerome O. Klein

    Should strategies of management of invasive disease in the febrile child without focus of infection (occult bacteremia) be reconsidered in communities with universal immunization of infants with the conjugate vaccines for Haemophilus influenzae type b and Streptococcus pneumoniae (PCV7)? The incidence of occult bacteremia is likely to decrease with the virtual elimination of H. influenzae type b and vaccine serotype pneumococcal invasive diseases. The number of children with fever coming to physicians’ offices, however, is unlikely to change. The challenge of distinguishing the febrile child with invasive bacterial disease who requires aggressive therapy from the febrile child who has a viral infection and requires only symptomatic therapy will persist. The bacteriology of invasive disease in infants and young children in 2002 will include pneumococcal serotypes not in PCV7; serotypes in PCV7 that occur in the unimmunized, partially immunized or fully immunized child (vaccine failures);Neisseria meningitidis;Salmonella spp., group A Streptococcus, Staphylococcus aureus and Gram-negative enteric bacilli. Management plans published in the 1990s suggested an aggressive diagnostic approach to the febrile child 3 to 36 months old who was toxic or had a temperature of >39°C. Diagnostic tests included white blood cell counts, cultures of blood and urine and chest radiograph and lumbar puncture as indicated by clinical signs and administration of parenteral ceftriaxone. Although PCV7 was extraordinarily effective in prevention of serotype-specific invasive pneumococcal disease in clinical trials, pediatricians need to know whether the results based on 38 000 enrollees will be maintained as millions of children are immunized. In addition questions about change in serotype of pneumococci causing invasive disease (serotype switching), herd immunity and durability of protection after immunization need to be answered. Until more experience is available to answer these questions, the febrile child without focus of infection should be managed without consideration of immunization with PCV7. Evaluation of the organism (serotype) and the host (acute and convalescent sera) should be undertaken for each case of invasive pneumococcal disease in this era of universal pneumococcal immunization.